SPINT2 mutations in the Kunitz domain 2 found in SCSD patients inactivate HAI-2 as prostasin inhibitor via abnormal protein folding and N-glycosylation.
Nanxi HuangQiaochu WangRobert B BernardChao-Yang ChenJe-Ming HuJehng-Kang WangKhee-Siang ChanMichael D JohnsonChen-Yong LinPublished in: Human molecular genetics (2024)
Mutations in the Kunitz-type serine protease inhibitor HAI-2, encoded by SPINT2, are responsible for the pathogenesis of syndromic congenital sodium diarrhea (SCSD), an intractable secretory diarrhea of infancy. Some of the mutations cause defects in the functionally required Kunitz domain 1 and/or subcellular targeting signals. Almost all SCSD patients, however, harbor SPINT2 missense mutations that affect the functionally less important Kunitz domain 2. How theses single amino acid substitutions inactivate HAI-2 was, here, investigated by the doxycycline-inducible expression of three of these mutants in HAI-2-knockout Caco-2 human colorectal adenocarcinoma cells. Examining protein expressed from these HAI-2 mutants reveals that roughly 50% of the protein is synthesized as disulfide-linked oligomers that lose protease inhibitory activity due to the distortion of the Kunitz domains by disarrayed disulfide bonding. Although the remaining protein is synthesized as monomers, its glycosylation status suggests that the HAI-2 monomer remains in the immature, lightly glycosylated form, and is not converted to the heavily glycosylated mature form. Heavily glycosylated HAI-2 possesses full anti-protease activity and appropriate subcellular targeting signals, including the one embedded in the complex-type N-glycan. As predicted, these HAI-2 mutants cannot suppress the excessive prostasin proteolysis caused by HAI-2 deletion. The oligomerization and glycosylation defects have also been observed in a colorectal adenocarcinoma line that harbors one of these SPINT2 missense mutations. Our study reveals that the abnormal protein folding and N-glycosylation can cause widespread HAI-2 inactivation in SCSD patents.
Keyphrases
- amino acid
- end stage renal disease
- protein protein
- ejection fraction
- newly diagnosed
- binding protein
- chronic kidney disease
- squamous cell carcinoma
- prognostic factors
- intellectual disability
- endothelial cells
- poor prognosis
- small molecule
- weight gain
- single molecule
- physical activity
- body mass index
- patient reported outcomes
- locally advanced
- drug delivery
- cell cycle arrest
- irritable bowel syndrome
- protein kinase
- endoplasmic reticulum stress
- simultaneous determination
- wild type
- liquid chromatography
- induced pluripotent stem cells